On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Becton Dickinson (Netherlands)

InstitutionResearch output, impact & collaborations

Becton Dickinson (Netherlands) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Becton Dickinson (Netherlands)?

ScholarIQrecord summary

Becton Dickinson (Netherlands) is a research organisation in Breda, NL. OpenAlex records 82 works and 1,122 citations for it. 41 researchers list it as their most recent affiliation.

How many works does Becton Dickinson (Netherlands) have?

ScholarIQindexed works

Becton Dickinson (Netherlands) has 82 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Becton Dickinson (Netherlands) →

How many citations does Becton Dickinson (Netherlands) have?

ScholarIQcitation count

Becton Dickinson (Netherlands) has 1,122 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Becton Dickinson (Netherlands) →

How many researchers are at Becton Dickinson (Netherlands)?

ScholarIQresearcher count

Becton Dickinson (Netherlands) has 41 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Becton Dickinson (Netherlands)?

ScholarIQavg h-index

Becton Dickinson (Netherlands) has an average h-index of 2 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Becton Dickinson (Netherlands)?

ScholarIQror

The ROR for Becton Dickinson (Netherlands) is on the source record.

Open the ROR →

What is the OpenAlex record for Becton Dickinson (Netherlands)?

ScholarIQopenalex

The OpenAlex for Becton Dickinson (Netherlands) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Becton Dickinson (Netherlands)?

ScholarIQtop researchers by citations

Kirsten van Nimwegen · Multiple Myeloma Research and Treatments

7 works82 citations

What are the most-cited papers on Becton Dickinson (Netherlands)?

ScholarIQmost cited works

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

Lieneke F.M. Ariëns, Kirsten van Nimwegen, M Shams, David De Bruin, Jorien van der Schaft, Harmieke van Os‐Medendorp, Marjolein de Bruin‐Weller

Acta Dermato Venereologica. 201977 CitationsOPEN ACCESS

P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK

Ivan Špıčka, Ido Lapidot, Maximilian Merz, Jakub Radocha, Martin Štork, Tomáš Jelı́nek, Alexandra Jungová, Jiří Minařík, J. Soukup, Michel van Speybroeck, Nolen Joy Perualila, Joris Diels, João Duarte Mendes, Kirsten van Nimwegen, Kai Strobel, S Wischlen, Henrik Sliwka, Blanca Gros Otero, Roman Hájek

HemaSphere. 20232 CitationsOPEN ACCESS

P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Philippe Moreau, Niels W.C.J. van de Donk, Michel Delforge, Hermann Einsele, Valerio De Stefano, Aurore Perrot, Britta Besemer, Charlotte Pawlyn, Lionel Karlin, Salomon Manier, Xavier Leleu, Pushpike Thilakarathne, Joris Diels, Katharine S. Gries, Nichola Erler-Yates, Kirsten van Nimwegen, Raúl Balsera Moraño, Vadim Strulev, Imène Haddad, Rachel Kobos, Jennifer Smit, Alexander Mclean Marshall, Mary Slavcev, María‐Victoria Mateos, Katja Weisel

HemaSphere. 20231 CitationsOPEN ACCESS

P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison

Michel Delforge, Sébastien Anguille, Julien Depaus, Nathalie Meuleman, Ann Van de Velde, Isabelle Van de Broek, Joris Diels, Nichola Erler-Yates, Sébastien Van Causenbroeck, Kirsten van Nimwegen, Sophie Vandervennet, Susanne Lub, Marie-Christiane Madeleine Vekemans

Clinical Lymphoma Myeloma & Leukemia. 20231 Citations

Inpatient vs outpatient treatment management with teclistamab in relapsed and refractory multiple myeloma: A cost and healthcare resource utilization analysis

Niels W.C.J. van de Donk, Ruth Wester, Inger S. Nijhof, Claire Albrecht, Raúl Balsera Moraño, Cristina Entrala, Kirsten van Nimwegen

Blood. 20251 CitationsOPEN ACCESS

How much of the research on Becton Dickinson (Netherlands) is open access?

ScholarIQopen access share

57%OPEN ACCESS

Gold

43%

Green

Hybrid

Bronze

14%

Closed

43%